Table 2.
Summary of characteristics of men who underwent biopsies in the first four screening rounds of the IMPACT study.
| Total | BRCA1+ | BRCA1– | p value | BRCA2+ | BRCA2– | p value | |
|---|---|---|---|---|---|---|---|
| Total biopsies (n) | 357a | 98 | 95 | 122 | 54 | ||
| Biopsy compliance (%) | 68 | 71 | 75 | 81 | 64 | ||
| Median PSA (ng/ml) to trigger biopsy (IQR) | 4.2 (3.5–5.6) | 4.2 (3.7–5.6) | 4.0 (3.5–4.8) | 0.1 | 4.5 (3.5–5.9) | 4.2 (3.4–6.2) | 0.8 |
| Median age (yr) at biopsy (IQR) | 61 (56–65) | 61 (56–64) | 61 (56–65) | 0.9 | 60 (56–64) | 64 (60–67) | <0.001 |
| Median time difference (d) PSA to biopsy (IQR) | 51 (27–89) | 56 (28–72) | 42 (22–79) | 0.3 | 57 (28–94) | 50 (25–87) | 0.1 |
| Median cores taken, n (IQR) | 10 (8–12) | 10 (9–12) | 10 (8–12) | 0.5 | 10 (8–12) | 10 (8–12) | 1 |
IQR = interquartile range; PSA = prostate-specific antigen.
a
Twelve biopsies contribute to both BRCA1 and BRCA2 controls, therefore the sum of mutation status will not match total cohort.